Tetanus is a serious, potentially life-threatening infectious disease caused by the Gram-positive anaerobic bacterium Clostridium tetani. Following wound contamination, the organism produces tetanospasmin, a potent neurotoxin that travels via peripheral motor nerves to the central nervous system and disrupts glycinergic and GABAergic inhibitory signaling, resulting in sustained, uncontrolled muscle contraction. Tetanus is not a genetic condition and has no hereditary component. A clinically distinct subtype, tetanus neonatorum, affects newborns following contamination of the umbilical stump and carries particularly high mortality rates in settings with limited vaccination infrastructure.

The hallmark presentation of tetanus includes trismus (jaw stiffness and inability to open the mouth, commonly called "lockjaw"), dysphagia, opisthotonus (arching of the spine and neck from dorsal muscle spasm), generalized muscle stiffness, and risus sardonicus, the characteristic fixed grimace produced by facial muscle contraction. These features are observed in the majority of affected individuals. Additional manifestations seen in a substantial proportion of patients include elevated generalized muscle tone (hypertonia), intermittent painful muscle spasms, stiff neck, tachycardia, and fever. In a smaller proportion of cases, respiratory distress from involvement of the respiratory musculature, hypertension, bradycardia, tremor, abdominal pain, and altered consciousness or coma may occur. Localized skin lesions at the wound portal of entry are frequently present.

Clostridium tetani spores are widely distributed in soil, dust, and animal feces. Infection follows introduction of spores into wound tissue—typically through cuts, puncture wounds, burns, injection sites, or surgical sites—where anaerobic conditions promote germination and toxin elaboration. Tetanospasmin is transported retrogradely along motor axons to inhibitory interneurons in the brainstem and spinal cord, where it cleaves synaptobrevin and blocks inhibitory neurotransmitter release. The condition is not transmitted between individuals and has no genetic etiology.

Tetanus is a clinical diagnosis based on the characteristic presentation of generalized muscle spasm, trismus, and risus sardonicus in the context of potential wound exposure or inadequate vaccination history. Laboratory culture of C. tetani from wound tissue is technically feasible but frequently negative, and a negative culture does not exclude the diagnosis. No routine blood test confirms tetanus. Assessment of wound characteristics and vaccination history is central to clinical evaluation. The severity classification system (Ablett scale) is commonly used to guide management intensity.

No specific FDA-approved pharmacological treatments are catalogued in this packet for tetanus. Clinical management of established tetanus is supportive, involving airway management, wound debridement, and neuromuscular control. Active clinical research programs, including several Phase III trials, are currently examining vaccine formulations and combined immunization strategies for tetanus prevention.

Tetanus carries a significant risk of life-threatening respiratory failure resulting from spasm of the diaphragm and chest wall musculature. Severity varies with the portal of entry, incubation period, and quantity of toxin produced. Generalized tetanus involving the trunk and respiratory muscles carries the greatest mortality risk. Tetanus neonatorum, affecting newborns, is associated with particularly high case fatality rates in resource-limited settings. Survival with intensive supportive care is possible, and neurological sequelae in survivors are uncommon when respiratory complications are managed successfully.

Active clinical trial records are present for tetanus, with current investigations focused primarily on vaccine formulation, combined immunization strategies, and immunogenicity of tetanus-containing combination vaccines across different age groups.